Pacira BioSciences (PCRX) Net Equity Issued and Repurchased (2012)

Pacira BioSciences' (PCRX) quarterly Net Equity Issued and Repurchased came in at -$45000.0 in Q2 2012.

Pacira BioSciences (PCRX) Net Equity Issued and Repurchased (2012) Analysis & Trends

Pacira BioSciences' Net Equity Issued and Repurchased history runs 1 years deep, the most recent figure standing at -$45000.0 for Q2 2012.

  • On a quarterly basis, Net Equity Issued and Repurchased changed N/A year-over-year to -$45000.0 in Q2 2012; TTM through Dec 2013 was -$45000.0, a N/A change from a year earlier, with the FY2012 full-year figure at $62.9 million, up 28.26% from the prior year.
  • Net Equity Issued and Repurchased steadied at -$45000.0 in Q2 2012 per PCRX's latest filing.
  • Across five years, Net Equity Issued and Repurchased topped out at -$45000.0 in Q2 2012 and bottomed at -$45000.0 in Q2 2012.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Equity Issued and Repurchased (Qtr)
1 Haleon 87.22 Bn 85.35 Bn - -
2 Teva Pharmaceutical Industries 39.60 Bn 35.87 Bn 1.97 Bn -
3 Zoetis 31.46 Bn 29.52 Bn 1.62 Bn -
4 Takeda Pharmaceutical 26.49 Bn 22.44 Bn 4.39 Bn -
5 United Therapeutics 23.03 Bn 20.88 Bn 648.10 Mn -
6 Universe Pharmaceuticals 23.03 Bn -10.56 Bn - -
7 Viatris 20.90 Bn 19.09 Bn 1.16 Bn 500,000.00
8 Neurocrine Biosciences 17.50 Bn 16.19 Bn 800.70 Mn 23.60 Mn
9 Elanco Animal Health 12.33 Bn 11.91 Bn 785.00 Mn -
10 Pacira BioSciences 1.05 Bn 846.97 Mn 140.96 Mn -

Historic Data

Download Data
DateValue
Jun 30, 2012 -45,000.00
Jun 30, 2012 -45,000.00